Latest Breaking News On - Gregory lubiniecki - Page 1 : vimarsana.com

FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy for Advanced Pleural Mesothelioma

The FDA granted priority review to an sBLA seeking the approval of pembrolizumab plus chemotherapy as frontline therapy in malignant pleural mesothelioma.

Gregory-lubiniecki
Merck-research-laboratories
Prescription-drug-user-fee-act

Keytruda-Lynparza combination misses survival targets in phase 3 lung cancer trial

Keytruda-Lynparza combination misses survival targets in phase 3 lung cancer trial
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Bymatthew-shinkle
Gregory-lubiniecki
Merck-research-laboratories

Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC

Pembrolizumab in combination with chemotherapy followed by maintenance olaparib did not meet its pre-specified statistical criteria of overall survival or progression free survival.

Gregory-lubiniecki
Merck-sharp-dohme
Merck-research-laboratories
Pembrolizumab-with-maintenance-olaparib
Maintenance-pemetrexed
Metastatic-nonsquamous-non-small-cell-lung-cancer
Merck-sharp
Provides-update
Plus-maintenance-lynparza

Pembrolizumab Plus Lenvatinib Misses Both Survival End Points in Advanced, Recurrent Endometrial Cancer

The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.

Gregory-lubiniecki
Corina-dutcus
Merck-research-laboratories
Global-clinical-development
Oncology-global-clinical-development-lead
Eisai-inc
Gynecologic-oncology
News
Pembrolizumab
Keytruda
Lenvatinib
Lenvima

acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.

Tokyo
Japan
Canada
United-states
Damini-chokshi
Peter-dannenbaum
John-infanti
Gregory-lubiniecki
Julie-cunningham
Corina-dutcus
Global-clinical-development
Merck-co-inc

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Japan
Tokyo
Canada
United-states
Damini-chokshi
Julie-cunningham
Peter-dannenbaum
Corina-dutcus
John-infanti
Gregory-lubiniecki
Merck-co-inc
Global-clinical-development

Eisai And Merck & Co., Inc., Rahway, NJ, USA Provide Update On Phase 3 LEAP-001 Trial Evaluating LENVIMA (Lenvatinib) Plus KEYTRUDA (Pembrolizumab) As...

Eisai And Merck & Co., Inc., Rahway, NJ, USA Provide Update On Phase 3 LEAP-001 Trial Evaluating LENVIMA (Lenvatinib) Plus KEYTRUDA (Pembrolizumab) As...
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Japan
Tokyo
Canada
United-states
Julie-cunningham
Peter-dannenbaum
Corina-dutcus
Gregory-lubiniecki
Damini-chokshi
John-infanti
United-states-research-laboratories-we
Global-clinical-development

Merck and Eisai combination endometrial cancer treatment fails to meet goals in clinical trial

Merck & Co. Inc. and Eisai Co. Ltd. said Friday that a late-stage trial of Merck’s blockbuster cancer treatment Keytruda in combination with Eisai’s drug...

Gregory-lubiniecki
Merck-research-laboratories
Eisai-co
Merck-co
Article-normal
Pharmaceuticals
Merck-amp-co-inc
Mrk
Eisai-co-ltd
Esalf

Merck and Eisai's Keytruda-Lenvima combo comes up short yet again, this time in endometrial cancer

Merck and Eisai's Keytruda-Lenvima combo comes up short yet again, this time in endometrial cancer
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Gregory-lubiniecki
Corina-dutcus
Merck-research-laboratories

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

RAHWAY, N.J.--(BUSINESS WIRE)--Oct 16, 2023--

Norway
United-states
Liechtenstein
Canada
Iceland
Switzerland
American
Solange-peters
Gregory-lubiniecki
Peter-dannenbaum
Damini-chokshi
Julie-cunningham